Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Enrolling by invitation2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

withdrawn125%
enrolling_by_invitation250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
enrolling_by_invitationphase_2

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

NCT06421532
enrolling_by_invitationnot_applicable

Treatment of SSD With tcVNS and taVNS

NCT07198542
terminatednot_applicable

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

NCT03869008
withdrawnnot_applicable

Study of Gammacore Sapphire for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)

NCT04071743

Clinical Trials (4)

Showing 4 of 4 trials
NCT06421532Phase 2

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

Enrolling By Invitation
NCT07198542Not Applicable

Treatment of SSD With tcVNS and taVNS

Enrolling By Invitation
NCT03869008Not Applicable

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Terminated
NCT04071743Not Applicable

Study of Gammacore Sapphire for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4